Nothing Special   »   [go: up one dir, main page]

SG11201805044WA - Compounds useful as kinase inhibitors - Google Patents

Compounds useful as kinase inhibitors

Info

Publication number
SG11201805044WA
SG11201805044WA SG11201805044WA SG11201805044WA SG11201805044WA SG 11201805044W A SG11201805044W A SG 11201805044WA SG 11201805044W A SG11201805044W A SG 11201805044WA SG 11201805044W A SG11201805044W A SG 11201805044WA SG 11201805044W A SG11201805044W A SG 11201805044WA
Authority
SG
Singapore
Prior art keywords
co7d
international
compounds
alderley
pct
Prior art date
Application number
SG11201805044WA
Inventor
Nicolas Guisot
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1522245.8A external-priority patent/GB201522245D0/en
Priority claimed from GBGB1613945.3A external-priority patent/GB201613945D0/en
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of SG11201805044WA publication Critical patent/SG11201805044WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 June 2017 (22.06.2017) WIPO I PCT (10) International Publication Number WO 2017/103611 Al 111111111111110111011111111111010111110111010111110111111110111011111111111110111111 (51) International Patent Classification: CO7D 405/14 (2006.01) CO7D 403/04 (2006.01) A61K 31/415 (2006.01) CO7D 405/04 (2006.01) A61K 31/4155 (2006.01) CO7D 405/06 (2006.01) C07D 231/14 (2006.01) CO7D 405/08 (2006.01) C07D 401/04 (2006.01) CO7D 413/06 (2006.01) C07D 401/06 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/GB2016/053968 (22) International Filing Date: 16 December 2016 (16.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1522245.8 16 December 2015 (16.12.2015) GB 1613945.3 15 August 2016 (15.08.2016) GB (71) Applicant: REDX PHARMA PLC [GB/GB]; Block 33F, Mereside, Alderley Park, Alderley Edge Cheshire SK10 4TG (GB). (72) Inventor: GUISOT, Nicolas; c/o Redx Pharma PLC, Block 33F, Mereside, Alderley Park, Alderley Edge Cheshire SK10 4TG (GB). (74) Agent: HGF LIMITED (LEEDS); 1 City Walk, Leeds Yorkshire LS11 9DX (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) W O 20 17 / 1036 11 Al (54) Title: COMPOUNDS USEFUL AS KINASE INHIBITORS (57) : This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specific - ally, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
SG11201805044WA 2015-12-16 2016-12-16 Compounds useful as kinase inhibitors SG11201805044WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1522245.8A GB201522245D0 (en) 2015-12-16 2015-12-16 Compounds useful as kinase inhibitors
GBGB1613945.3A GB201613945D0 (en) 2016-08-15 2016-08-15 Compounds useful as kinase inhibitors
PCT/GB2016/053968 WO2017103611A1 (en) 2015-12-16 2016-12-16 Compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
SG11201805044WA true SG11201805044WA (en) 2018-07-30

Family

ID=57590725

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201805044WA SG11201805044WA (en) 2015-12-16 2016-12-16 Compounds useful as kinase inhibitors
SG10202012498TA SG10202012498TA (en) 2015-12-16 2016-12-16 Compounds useful as kinase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202012498TA SG10202012498TA (en) 2015-12-16 2016-12-16 Compounds useful as kinase inhibitors

Country Status (37)

Country Link
US (7) US10695323B2 (en)
EP (2) EP3782994A1 (en)
JP (3) JP6731483B2 (en)
KR (2) KR20210018530A (en)
CN (9) CN113603645B (en)
AU (4) AU2016373530B2 (en)
CA (1) CA3008488C (en)
CL (1) CL2018001591A1 (en)
CO (1) CO2018006164A2 (en)
CR (1) CR20180367A (en)
CY (2) CY1123561T1 (en)
DK (1) DK3390395T3 (en)
EA (1) EA035132B1 (en)
ES (1) ES2828431T3 (en)
FI (1) FIC20240004I1 (en)
FR (1) FR24C1009I1 (en)
HK (1) HK1263254A1 (en)
HR (1) HRP20201835T1 (en)
HU (2) HUE051921T2 (en)
IL (4) IL285976B2 (en)
LT (1) LT3390395T (en)
MA (2) MA49809A1 (en)
MD (1) MD3390395T2 (en)
MX (2) MX2018007267A (en)
NL (1) NL301262I2 (en)
NO (1) NO2024008I1 (en)
NZ (1) NZ743553A (en)
PE (3) PE20220507A1 (en)
PH (1) PH12018501268A1 (en)
PT (1) PT3390395T (en)
RS (1) RS60982B1 (en)
SG (2) SG11201805044WA (en)
SI (1) SI3390395T1 (en)
TN (1) TN2018000213A1 (en)
UA (2) UA127863C2 (en)
WO (1) WO2017103611A1 (en)
ZA (4) ZA201804137B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
AU2016322063A1 (en) 2015-09-16 2018-04-12 Loxo Oncology, Inc. Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
CN113603645B (en) 2015-12-16 2024-10-29 洛克索肿瘤学股份有限公司 Compounds useful as kinase inhibitors
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
CA3096139A1 (en) * 2018-04-06 2019-10-10 Black Belt Tx Ltd Atf6 inhibitors and uses thereof
JP6995195B2 (en) * 2018-05-18 2022-02-04 富士フイルム株式会社 A method for producing a 3-difluoromethylpyrazole compound, a method for producing a 3-difluoromethylpyrazole-4-carboxylic acid compound, and a pyrazolidine compound.
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
CN114206852A (en) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 Plasma kallikrein inhibitors
WO2021053234A1 (en) * 2019-09-19 2021-03-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Compounds and compositions for treating kidney disease
CN110724135B (en) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 Esalapril Lin Zhongjian body and preparation method thereof
WO2021113497A1 (en) 2019-12-06 2021-06-10 Loxo Oncology, Inc. Dosing of a bruton's tyrosine kinase inhibitor
CN115443277A (en) * 2020-03-12 2022-12-06 重庆复尚源创医药技术有限公司 Compounds as kinase inhibitors
TW202317099A (en) * 2020-09-10 2023-05-01 美商絡速藥業公司 Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1h-pyrazole-4-carboxamide
CN112386597B (en) * 2020-10-15 2022-03-15 天津济坤医药科技有限公司 Application of zebritinib in preparation of medicine for treating pulmonary fibrosis diseases
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022228302A1 (en) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Heteroaromatic carboxamide compounds and its use
AU2022274771B2 (en) 2021-05-14 2024-10-10 Loxo Oncology, Inc. Cocrystalline forms of a bruton's tyrosine kinase inhibitor
CN115557933B (en) * 2021-07-01 2024-08-16 杭州和正医药有限公司 Bruton tyrosine kinase and mutant degradation agent, composition and application thereof
CN115611810A (en) * 2021-07-16 2023-01-17 深圳市塔吉瑞生物医药有限公司 Substituted pyrazole compounds, compositions containing the same and uses thereof
MX2024007328A (en) 2021-12-14 2024-09-30 Crossfire Oncology Holding B V Macrocyclic btk inhibitors.
WO2023143355A1 (en) * 2022-01-28 2023-08-03 Hansoh Bio Llc Azacycle amide derivative, preparation methods and medicinal uses thereof
WO2023174397A1 (en) * 2022-03-18 2023-09-21 Insilico Medicine Ip Limited Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
CN115894376A (en) * 2022-12-15 2023-04-04 南京雷正医药科技有限公司 Aromatic amide compound, pharmaceutical composition and application thereof
WO2024176164A1 (en) 2023-02-22 2024-08-29 Assia Chemical Industries Ltd. Solid state form of pirtobrutinib

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
CN1390219A (en) 1999-09-17 2003-01-08 艾博特股份有限两合公司 Pyrazolopyrimidines as therapeutic agents
US6291504B1 (en) * 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2008063287A2 (en) * 2006-10-06 2008-05-29 Abbott Laboratories Novel imidazothiazoles and imidazoxazoles
CA2668286C (en) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
CA3001152A1 (en) 2007-03-28 2008-10-09 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2307025B1 (en) 2008-07-16 2017-09-20 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2010010154A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
KR101580714B1 (en) 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 The use of inhibitors of bruton's tyrosine kinase (btk)
TWI582091B (en) 2010-06-30 2017-05-11 艾諾屋製藥公司 Sgc stimulators
MX355728B (en) 2011-05-17 2018-04-27 Univ California Kinase inhibitors.
CN103534258B (en) 2011-05-17 2016-09-14 普林斯匹亚生物制药公司 Tyrosine kinase inhibitor
CA2841080A1 (en) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
MX368112B (en) 2012-06-18 2019-09-18 Principia Biopharma Inc Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases.
US9572811B2 (en) 2012-08-03 2017-02-21 Principia Biopharma Inc. Treatment of dry eye
MX2015001802A (en) * 2012-08-10 2015-05-07 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors.
GB201214750D0 (en) * 2012-08-17 2012-10-03 Respivert Ltd Compounds
ES2625944T3 (en) 2012-11-02 2017-07-21 Pfizer Inc. Bruton tyrosine kinase inhibitors
CN103848810A (en) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 Bruton's tyrosine kinases inhibitor
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
RU2677884C2 (en) * 2013-09-30 2019-01-22 Гуанчжоу Иннокэа Фарма Тек Ко., Лтд. Substituted nicotinimide inhibitors of btk, their preparation and use in treatment of cancer, inflammation and autoimmune diseases
WO2015075051A1 (en) * 2013-11-19 2015-05-28 Universitaet Des Saarlandes Allosteric inhibitors of atypical protein kinases c
US9637486B2 (en) 2013-12-20 2017-05-02 Merck Sharp & Dohme Corp. Btk inhibitors
PT3107544T (en) 2014-02-21 2021-01-05 Principia Biopharma Inc Salts and solid form of a btk inhibitor
GB201404987D0 (en) * 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
CN105085474B (en) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 Shandong tyrosine kinase inhibitor
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
PE20171240A1 (en) 2015-01-28 2017-08-24 Bayer Pharma AG DERIVATIVES OF 4H-PYRROL [3,2-C] PYRIDIN-4-ONA
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
JO3633B1 (en) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
AU2016322063A1 (en) 2015-09-16 2018-04-12 Loxo Oncology, Inc. Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
JOP20160198B1 (en) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
JP6728382B2 (en) 2015-12-16 2020-07-22 エコラブ ユーエスエイ インク Peroxyformic acid composition for membrane filtration purification
CN113603645B (en) 2015-12-16 2024-10-29 洛克索肿瘤学股份有限公司 Compounds useful as kinase inhibitors
WO2017106429A2 (en) 2015-12-16 2017-06-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
EA036736B1 (en) 2015-12-16 2020-12-14 Бристол-Майерс Сквибб Компани Heteroarylhydroxypyrimidinones as agonists of the apj receptor
KR20180095871A (en) 2015-12-16 2018-08-28 프리오스타 피티와이 엘티디 Dendrimer and its combination

Also Published As

Publication number Publication date
ZA202100544B (en) 2023-06-28
CL2018001591A1 (en) 2018-09-28
EP3390395A1 (en) 2018-10-24
US20190000806A1 (en) 2019-01-03
UA122258C2 (en) 2020-10-12
FIC20240004I1 (en) 2024-03-01
IL281067A (en) 2021-04-29
PE20220502A1 (en) 2022-04-07
MA55064A (en) 2021-09-29
NL301262I2 (en) 2024-04-24
CN108473481A (en) 2018-08-31
US20230372298A1 (en) 2023-11-23
CN114605327A (en) 2022-06-10
NZ743553A (en) 2022-08-26
CN114621146A (en) 2022-06-14
AU2016373530B2 (en) 2021-01-21
JP7086140B2 (en) 2022-06-17
MA49809A1 (en) 2021-08-31
CN108473481B (en) 2022-04-19
IL276283A (en) 2020-09-30
JP2022120013A (en) 2022-08-17
CN114591242A (en) 2022-06-07
AU2016373530A1 (en) 2018-07-05
IL285976B1 (en) 2023-06-01
AU2021225161B2 (en) 2023-08-03
RS60982B1 (en) 2020-11-30
TN2018000213A1 (en) 2019-10-04
IL259923A (en) 2018-07-31
US11471441B2 (en) 2022-10-18
US10918622B2 (en) 2021-02-16
CN114634447A (en) 2022-06-17
US11826351B2 (en) 2023-11-28
SG10202012498TA (en) 2021-01-28
PE20181449A1 (en) 2018-09-12
IL281067B (en) 2022-04-01
US10342780B2 (en) 2019-07-09
HK1263254A1 (en) 2020-02-21
US20210093611A1 (en) 2021-04-01
CN114716381A (en) 2022-07-08
CN113636978B (en) 2024-10-29
EP3390395B1 (en) 2020-09-09
AU2021201811A1 (en) 2021-04-22
DK3390395T3 (en) 2020-09-28
LT3390395T (en) 2020-11-25
CY2024003I1 (en) 2024-09-20
JP7419437B2 (en) 2024-01-22
MX2021003478A (en) 2022-07-25
AU2021225161A1 (en) 2021-09-30
EA201891268A1 (en) 2018-11-30
US20180362512A1 (en) 2018-12-20
JP2018538307A (en) 2018-12-27
SI3390395T1 (en) 2020-11-30
BR112018012341A2 (en) 2018-12-04
CA3008488A1 (en) 2017-06-22
CN113636978A (en) 2021-11-12
NO2024008I1 (en) 2024-02-29
CO2018006164A2 (en) 2018-09-20
ZA201804137B (en) 2022-08-31
HUS2400003I1 (en) 2024-03-28
US20200276162A1 (en) 2020-09-03
CY1123561T1 (en) 2022-03-24
HRP20201835T1 (en) 2021-01-08
MX2018007267A (en) 2018-11-09
JP2020172535A (en) 2020-10-22
ZA202107472B (en) 2023-03-29
KR102215792B1 (en) 2021-02-16
CR20180367A (en) 2018-11-12
CN114573510A (en) 2022-06-03
PH12018501268A1 (en) 2019-02-18
WO2017103611A1 (en) 2017-06-22
IL276283B (en) 2021-03-25
UA127863C2 (en) 2024-01-31
CA3008488C (en) 2023-10-10
US10464905B2 (en) 2019-11-05
AU2021201811B2 (en) 2022-01-27
PT3390395T (en) 2020-11-03
US10695323B2 (en) 2020-06-30
IL285976B2 (en) 2023-10-01
JP6731483B2 (en) 2020-07-29
CN113603645B (en) 2024-10-29
HUE051921T2 (en) 2021-03-29
KR20180115261A (en) 2018-10-22
PE20220507A1 (en) 2022-04-07
IL259923B (en) 2020-08-31
US20220062239A1 (en) 2022-03-03
MD3390395T2 (en) 2021-02-28
IL285976A (en) 2021-10-31
EP3782994A1 (en) 2021-02-24
CN113603645A (en) 2021-11-05
AU2021225162A1 (en) 2021-09-30
ZA202107471B (en) 2023-03-29
AU2021225162B2 (en) 2023-08-03
FR24C1009I1 (en) 2024-05-24
KR20210018530A (en) 2021-02-17
US20190135762A1 (en) 2019-05-09
EA035132B1 (en) 2020-04-30
ES2828431T3 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201808878UA (en) Heterocyclic compounds as ret kinase inhibitors
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201810940XA (en) Methods of treating pancreatic cancer
SG11201805001UA (en) Method of treating influenza a
SG11201903770UA (en) Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders